GI Innovation, Inc. (KOSDAQ:358570)
South Korea · Delayed Price · Currency is KRW 18,520
+100 (0.54%)
Nov 20, 2025, 3:30 PM KST
GI Innovation Revenue
GI Innovation had revenue of 125.82M KRW in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to 338.09M, down -92.89% year-over-year. In the year 2024, GI Innovation had annual revenue of 24.28M, down -99.54%.
Revenue (ttm)
338.09M
Revenue Growth
-92.89%
P/S Ratio
3,469.14
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.17T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24.28M | -5.29B | -99.54% |
| Dec 31, 2023 | 5.32B | 1.82B | 51.97% |
| Dec 31, 2022 | 3.50B | -2.10B | -37.50% |
| Dec 31, 2021 | 5.60B | -5.42B | -49.17% |
| Dec 31, 2020 | 11.02B | 7.50B | 213.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |